Subtotal $0.00
Shop Now
Mounjaro vs Zepbound is a comparison of two brands of one drug. Both contain tirzepatide, a weekly injection from Eli Lilly that activates two hormone receptors, GIP and GLP-1. Mounjaro is approved for type 2 diabetes, including in children 10 and older since December 2025 and, since August 2026, to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Zepbound is approved for long-term weight management and for obstructive sleep apnea in adults with obesity. The strengths are identical, and both come in pens and vials. This guide compares Zepbound vs Mounjaro using the labels revised in August 2026.
Peptide Labs does not sell Mounjaro, Zepbound or any prescription drug. This article is general information, not medical advice. Which product, if any, suits a person is a decision for a licensed prescriber.
Key Takeaways
- Mounjaro and Zepbound both contain tirzepatide, a dual GIP and GLP-1 receptor agonist.
- Mounjaro is approved for type 2 diabetes in adults and children 10+, plus CV risk reduction in adults.
- Zepbound is approved for weight management and moderate to severe sleep apnea in adults with obesity.
- They share the same six strengths, the same boxed warning and the same core safety information.
- Zepbound vials and multi-dose KwikPens are sold through Lilly's LillyDirect self-pay pharmacy.
Mounjaro vs Zepbound at a glance
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| First FDA approval | May 2022 | November 2023 |
| Main approved use | Blood sugar control in type 2 diabetes, adults and children 10+ | Long-term weight management in adults with obesity, or overweight with a weight-related condition |
| Other approved uses | Lowering the risk of heart attack, stroke and CV death in adults with type 2 diabetes at high risk (August 2026) | Moderate to severe obstructive sleep apnea in adults with obesity (December 2024) |
| Needs type 2 diabetes? | Yes | No |
| Approved ages | Adults; children 10+ for blood sugar control | Adults |
| Strengths on the label | 2.5, 5, 7.5, 10, 12.5 and 15 mg | 2.5, 5, 7.5, 10, 12.5 and 15 mg |
| Devices on the label | Single-dose pens, single-dose vials, multi-dose vials, KwikPen | Single-dose pens, single-dose vials, multi-dose vials, KwikPen |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
Are Mounjaro and Zepbound the same?
The medicine inside is the same. Tirzepatide is a peptide built on the GIP hormone sequence and modified so it lasts about five days in the body, which allows once-weekly injections. What differs is the label: each brand was studied in its own trials and approved for specific uses. Mounjaro’s approval rests on the SURPASS diabetes trials; Zepbound’s rests on the SURMOUNT weight-management trials and the SURMOUNT-OSA sleep apnea trials. For the molecule itself, see our tirzepatide profile.
The Zepbound label states that it should not be used with other tirzepatide-containing products or with any GLP-1 receptor agonist, which in practice means someone would take one tirzepatide brand, not both.
Mounjaro: type 2 diabetes and heart risk
Mounjaro was approved in May 2022 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Two changes came recently:
- Children 10 and older (December 2025). The label added pediatric type 2 diabetes after a trial in 97 young people with an average age of 15.
- Cardiovascular risk (August 2026). The label added an indication to lower the risk of cardiovascular death, heart attack or stroke in adults with type 2 diabetes at high risk. It is based on SURPASS-CVOT, a trial of 13,299 adults with type 2 diabetes and heart disease that compared tirzepatide with another GLP-1 drug, dulaglutide, rather than placebo. Over a median of about four years, major cardiovascular events occurred in 12.2% on tirzepatide and 13.1% on dulaglutide. The label reports that tirzepatide was non-inferior, but superiority was not established.
Mounjaro is not approved for weight management, although weight loss was seen in its diabetes trials.
Zepbound: weight management and sleep apnea
Zepbound was approved in November 2023, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. In December 2024 it became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity. Zepbound is not approved for blood sugar control or for anyone under 18. In the SURMOUNT-1 trial, adults without diabetes lost about 15% to 21% of body weight on average over 72 weeks depending on dose, versus about 3% on placebo; the semaglutide vs tirzepatide guide covers these results and the head-to-head trial with semaglutide.
Pens, vials and KwikPens
Both August 2026 labels list the same four presentations in the same six strengths:
- Single-dose prefilled pens, one pen per weekly dose.
- Single-dose vials, used with a syringe and needle.
- Multi-dose vials holding four weekly doses.
- A single-patient-use KwikPen holding four weekly doses, which must never be shared, even with a new needle.
How patients get them differs. Lilly began selling Zepbound single-dose vials on August 27, 2024, through the self-pay pharmacy part of its LillyDirect service, and later added higher strengths. According to Lilly’s medical information page, Zepbound vials and multi-dose KwikPens are available only through LillyDirect’s self-pay channel, while single-dose pens can also be filled through its insurance pharmacy and retail pharmacies. A prescription is required in every case. Using a vial means drawing up a dose with a syringe, which a pharmacist or clinician should demonstrate.
Zepbound vs Mounjaro side effects
The two labels share the same boxed warning about thyroid C-cell tumors seen in rats and the same warnings about pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe digestive reactions, allergic reactions, diabetic eye complications and anesthesia. Both advise people using birth control pills to switch to a non-oral method, or add a barrier method, for a period after starting and after each dose increase. The percentages differ because the trials differed: nausea affected 25% to 29% in Zepbound’s weight trials versus 12% to 18% in Mounjaro’s diabetes trials. Zepbound’s label dropped its suicidal-thoughts warning in February 2026 after an FDA review found no increased risk; Mounjaro never carried one. Our tirzepatide side effects guide has the full tables.
Coverage and choosing between them
In practice, the choice between Mounjaro and Zepbound usually follows the diagnosis: Mounjaro for type 2 diabetes, Zepbound for weight management or sleep apnea without diabetes. Insurance plans tend to cover diabetes drugs more consistently than weight-management drugs, and coverage for the latter varies widely between plans. A prescriber, pharmacist or the plan itself can confirm what applies. For semaglutide’s equivalent pair, see Wegovy vs Ozempic, and for the oral question, is there a tirzepatide pill?
Frequently Asked Questions
Is Mounjaro the same as Zepbound?
Both contain tirzepatide in the same strengths. Mounjaro is approved for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes; Zepbound is approved for weight management and obstructive sleep apnea in adults with obesity.
Can Mounjaro be used for weight loss?
Mounjaro is not FDA-approved for weight management; Zepbound is the tirzepatide brand approved for that use. Prescribing Mounjaro only for weight loss would be off-label.
Is Zepbound stronger than Mounjaro?
No. Both labels list the same six strengths, from 2.5 mg to 15 mg. The difference is the approved use, not the strength.
Can children use Mounjaro or Zepbound?
Since December 2025, Mounjaro is approved for blood sugar control in children 10 and older with type 2 diabetes. Zepbound is approved only for adults.
Where do Zepbound vials come from?
Zepbound vials and multi-dose KwikPens are sold through LillyDirect’s self-pay pharmacy with a prescription. Single-dose pens are available through insurance and pharmacies.
Do Mounjaro and Zepbound have the same side effects?
They share the same warnings. Digestive side effects were reported more often in Zepbound’s weight trials than in Mounjaro’s diabetes trials.
This article is general information, not medical advice. Peptide Labs does not sell prescription drugs, including any product named here. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed September 2026.
Related guides: How Long Does Ozempic Take to Work? Labels and Trials Explained, Zepbound and Alcohol: What GLP-1 Labels and Research Say, GLP-1 for Weight Loss: What the Trials Actually Showed, Zepbound Before and After: Results From the SURMOUNT Trials.